This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The outcomes assessed in the review were: the probability of conversion to OpenDN in the LapDN arm; the probability of major donor peri-operative complications with OpenDN and LapDN (i.e. death, bleeding necessitating transfusion, major cardiac event and pneumonia); the probability of the donor requiring narcotic analgesics 4 weeks after surgery with OpenDN and LapDN; the probability of the donor not returning to work 4 weeks after the surgery with OpenDN and LapDN; the relative risk reduction (RRR) in LapDN for donor not working at 4 weeks; the RRR in LapDN arm for donor with pain at 4 weeks after surgical intervention; the RRR in OpenDN arm for severe operative complications; the decreased risk (relative risk, RR) of the donor not returning to work in the absence of pain.
Study designs and other criteria for inclusion in the review
The authors reported that the studies included in the review were non-randomised trials, with the best evidence obtained mainly from prospective case series studies, although the probabilities for LapDN were derived from 5-year observational studies, and the probabilities for OpenDN were derived from the largest published retrospective studies.
Sources searched to identify primary studies
The authors reported that MEDLINE was searched from 1966 to 2000.
Criteria used to ensure the validity of primary studies
Not reported.
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Two studies were included in the review.
Methods of combining primary studies
The method used by the authors to combine the results from the primary studies included in the review was not stated.
Investigation of differences between primary studies
The authors reported the lowest and highest values of the different outcomes assessed in the review.
Results of the review
The results of the review were as follows:
The probability of conversion to OpenDN in the LapDN arm was 0.1 (with 0 as the lowest value and 0.2 as the highest value).
The probability of major donor peri-operative complications with OpenDN and LapDN, respectively, were 0.073 (with 0.015 as the lowest value and 0.11 as the highest value) and 0.11 (with 0.07 as the lowest value and 0.13 as the highest value).
The probability of the donor requiring narcotic analgesics because of pain 4 weeks after surgery was: 0.11 (with 0.05 as the lowest value and 0.35 as the highest value) with OpenDN and 0 (with 0.11 as the highest value) with LapDN.
The probability of the donor not returning to work 4 weeks after the surgery was 0.54 (with 0.28 as the lowest value and 1 as the highest value) with OpenDN, and 0.28 (with 0.09 as the lowest and 0.54 as the highest values) with LapDN.
The relative risk reduction (RRR) in LapDN (when compared to OpenDN) for donor not working at 4 weeks was 0.48 (with 0.46 as the lowest and 0.68 as the highest values).
The RRR in LapDN arm (when compared to OpenDN) for donor with pain at 4 weeks after surgical intervention was 1 (with the lowest value equal to 0.69).
The RRR in the OpenDN arm (when compared to LapDN) for severe operative complications was 0.34 (with the lowest value equal to 0.15 and the highest equal to 0.79).
The decreased risk of the donor not returning to work in the absence of pain was 0.99 (with the lowest value equal to 0.8 and the highest value equal to 1).
Methods used to derive estimates of effectiveness
The authors reported that no relevant utilities for the post-operative health states of the donors were identified in the literature and, therefore, a panel of 14 experts in transplantation was created to derive these utilities, using time-trade off techniques.
Estimates of effectiveness and key assumptions
The utilities for donor events were estimated as follows: the utility of a donor not working at 4 weeks was estimated as 0.67 (with the lowest value equal to 0.4 and the highest value equal to 1); the utility of a donor who experienced pain at 4 weeks after the intervention was 0.76 (with the lowest value equal to 0.5 and the highest equal to 1); and the utility of a donor experiencing severe complications was valued as 0.18 (with the lowest value equal to 0.04 and the highest equal to 0.33).
These utilities were assumed to be independent of the treatment arms. The authors assumed that these utilities reflected the utilities of the general population or of patients in these health states.
Measure of benefits used in the economic analysis
The outcome measures used in the economic analysis were quality-adjusted life-years (QALYs). Utilities for health states were derived from an expert panel (see 'Methods Used to Derive Estimates of Effectiveness' and 'Estimates of Effectiveness and Key Assumptions' sections, reported above). The authors reported that, in order to adjust the utilities of the different health states that the donors could experience, the model was adjusted for the length of time the individual was in that state. Three time periods were considered: inpatient phase (length 1 week), where severe complications could occur; early outpatient phase (length 4 weeks), where pain and work-related complications could occur; and late outpatient phase, where pain and work-related complications could occur again. The authors assumed that any complication occurring within a period would last for the whole period.
Direct costs
Resource quantities and costs were reported separately. The direct costs considered at analysis were those of the health service, and included: the inpatient costs (i.e. costs per LapDN or per OpenDN, disposable instruments such as pneumosleeve, endoshears, endoGIA handle and cartridge, surgeon fee and anaesthetic fee); the costs caused by complications (i.e. the intensive care unit costs); and the outpatient costs (i.e. clinic visits, physician fee for clinic visit, outpatient dispensing fee, and drug costs, including Colace, Tylenol plain, Tylenol ES, Endocet and Tylenol 3). The decision analytic model was used to extrapolate the costs for the whole period of follow-up of the patients (three months). The estimation of the costs was based on actual data. The costs of surgical procedures, inpatient hospital stay, complication costs, clinical space and visits were obtained from St. Michael's Hospital Decision Support Department, using cost-per-weighted case (with data from 2000). A sample of 21 patients who received either LapDN or OpenDN in
